The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype

Pharmacogenetics

Volumn 12, Issue 8, 2002, Pages 647-653

  Maitland van der Zee, Anke Hilse ^a,b   Stricker, Bruno H Ch ^b   Klungel, Olaf H ^a   Kastelein, John J P ^c   Hofman, Albert ^b   Witteman, Jacqueline C M ^b   Breteler, Monique M B ^b   Leufkens, Hubertus G M ^a   Van Duijn, Cornelia M ^b   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein E genotype; Effectiveness; Pharmacogenetics; Statins

Indexed keywords

APOLIPOPROTEIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALLELE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SENESCENCE; STROKE;

AGED; APOLIPOPROTEINS E; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS;

EID: 12244296189     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200211000-00009     Document Type: Article

References (28)

1. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatine Survival Study. Lancet 1994; 344:1383-1389.
2. Sacks F, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatine on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 336:1001-1009.
3. Anonymous. Prevention of cardiovascular events and death with pravastatine in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998; 339:1349-1357.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, et al. Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia. New Eng J Med 1995; 333:1301-1307.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatine in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360:7-22.
7. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981; 33:11-24.
8. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8:1-21.
9. Sanllehy C, Casals E, Rodriguez-Villar C, Zambon D, Ojuel J, Ballesta AM, et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 1998; 47:560-565.
10. Hagberg JM, Wilund KR, Ferrell RE. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels Physiol Genomics 2000; 4:101-108.
11. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36:1572-1578.
12. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein (a) and insulin. Atherosclerosis 1997; 129:231-239.
13. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113:157-166.
14. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993; 42:895-901.
15. Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and nonfamilial hypercholesterolaemia. J Intern Med 1991; 230:397-405.
16. De Knijff P, Stalenhoef AF, Mol MJ, Gevers Leuven JA, Smit J, Erkelens DW, et al. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia, Atherosclerosis 1990; 83:89-97.
17. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990; 39:150-154.
18. Pena R, Lahoz C, Mostaza JM, Jimenez J, Subirats E, Pinto X, et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting, J Intern Med 2002; 261:518-525.
19. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian Simvastatin Survival Study. Circulation 2000; 101:1366-1371.
20. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991; 7:403-422.
21. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96:1432-1437.
22. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308:373-379.
23. WHO. Guidelines for ATC Classification. Oslo: WHO Collaborating centre for drug statistics methodology - Nordic Council on medicines, 1990.
24. van Duijn CM, de Knijff P, Wehnert A, De Voecht J, Bronzova JB, Havekes LM, et al. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early onset Alzheimer's disease and a reduced survival. Ann Neurol 1995; 37:605-610.
25. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337:1158-1159.
26. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene - Environment interaction: Case-control studies with no controls! Am J Epidemiol 1996; 144:207-213.
27. Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: An autopsy study. Circulation 1999; 100:608-613.
28. Kuivenhoven J, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AVG, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Eng J Med 1998; 338:86-93.